Physician profile
Daniel Smith
NPI 1396705430
$1,431.86
in general payments reported to CMS, 2019-2025
21 companies · $26.61 in 2025
The $26.61 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $635 · 2020: $120 · 2022: $210 · 2023: $300 · 2024: $139 · 2025: $26.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $466.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $394.78 | 2019-2023 | Dovato, Cabenuva |
| Gilead Sciences, INC. | $232.98 | 2019-2024 | |
| Smith+Nephew, INC. | $137.08 | 2019-2023 | Collagenase Santyl |
| Abbvie INC. | $91.23 | 2022-2025 | |
| Tactile Systems Technology INC | $75.30 | 2024 | Entre Plus, Flexitouch Plus |
| Merck Sharp & Dohme LLC | $67.49 | 2019-2023 | Dificid |
| Janssen Biotech, INC. | $64.19 | 2019-2023 | Symtuza |
| Astellas Pharma US INC | $43.35 | 2019 | |
| Organogenesis INC. | $37.90 | 2023 | Puraply |
| Insmed, INC. | $36.16 | 2019-2022 | |
| La Jolla Pharmaceutical Company | $36.04 | 2022-2023 | Xerava |
| Paratek Pharmaceuticals, INC. | $32.94 | 2020-2023 | Nuzyra |
| Allergan, INC. | $28.45 | 2019 | |
| Vyera Pharmaceuticals, LLC | $27.79 | 2019 | |
| Abbott Laboratories | $26.87 | 2023 | Freestyle Libre 3 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $21.22 | 2019 | |
| Philips North America LLC | $18.99 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $16.87 | 2019 | |
| Napo Pharmaceuticals INC | $14.87 | 2019 | |
| Melinta Therapeutics, LLC | $14.57 | 2019 | |
| Romark Laboratories, Lc | $12.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.